| Literature DB >> 32727860 |
Laura K Boelsen1,2, Eileen M Dunne1,2, Katherine A Gould3,4, F Tupou Ratu5, Jorge E Vidal6, Fiona M Russell1,2, E Kim Mulholland1,2,7, Jason Hinds3,4, Catherine Satzke8,2,9.
Abstract
Streptococcus pneumoniae (the pneumococcus) carriage is commonly used to measure effects of pneumococcal vaccines. Based on findings from culture-based studies, the World Health Organization recommends both nasopharyngeal (NP) and oropharyngeal (OP) sampling for detecting adult carriage. Given evidence of potential confounding by other streptococci, we evaluated molecular methods for pneumococcal identification and serotyping from 250 OP samples collected from adults in Fiji, using paired NP samples for comparison. Samples were screened using lytA quantitative PCR (qPCR), as well as pneumococcal identification and serotyping conducted by DNA microarray. A subset of OP samples were characterized by latex sweep agglutination and multiplex PCR. Alternate qPCR assays (piaB and bguR) for pneumococcal identification were evaluated. The lytA qPCR was less specific and had poor positive predictive value (PPV) in OP samples (88% and 26%, respectively) compared with NP samples (95% and 64%, respectively). Using additional targets piaB and/or bguR improved qPCR specificity in OP, although the PPV (42 to 53%) was still poor. Using microarray, we found that 102/107 (95%) of OP samples contained nonpneumococcal streptococci with partial or divergent complements of pneumococcal capsule genes. We explored 91 colonies isolated from 11 OP samples using various techniques, including multiplex PCR, latex agglutination, and microarray. We found that nonpneumococcal streptococci contribute to false positives in pneumococcal serotyping and may also contribute to spurious identification by qPCR. Our results highlight that molecular approaches should include multiple loci to minimize false-positive results when testing OP samples. Regardless of method, pneumococcal identification and serotyping results from OP samples should be interpreted with caution.IMPORTANCE Streptococcus pneumoniae (the pneumococcus) is a significant global pathogen. Accurate identification and serotyping are vital. In contrast with World Health Organization recommendations based on culture methods, we demonstrate that pneumococcal identification and serotyping with molecular methods are affected by sample type. Results from oropharyngeal samples from adults were often inaccurate. This is particularly important for assessment of vaccine impact using carriage studies, particularly in low- and middle-income countries where there are significant barriers for disease surveillance.Entities:
Keywords: PCR; Streptococcus pneumoniaezzm321990; carriage; genotypic; identification; nasopharyngeal; oropharyngeal; serotyping
Mesh:
Year: 2020 PMID: 32727860 PMCID: PMC7392543 DOI: 10.1128/mSphere.00478-20
Source DB: PubMed Journal: mSphere ISSN: 2379-5042 Impact factor: 4.389
Pneumococcal carriage results obtained from paired nasopharyngeal and oropharyngeal swabs
| Microarray result | NP | OP | |
|---|---|---|---|
| Positive ( | Positive | 13 | 7 |
| Negative | 0 | 2 | |
| No growth | 1 | 0 | |
| Equivocal ( | Positive | 7 | 3 |
| Negative | 0 | 30 | |
| No growth | 12 | 1 | |
| Negative (no | 217 | 207 |
Samples were screened by lytA quantitative real-time PCR, and positive and equivocal samples were further tested by culture on selective agar and DNA microarray.
NP, nasopharyngeal.
OP, oropharyngeal.
One NP sample was nonculturable and therefore not tested by microarray.
Equivocal samples with no growth were considered negative for pneumococci (54).
Evaluation of lytA, bguR, and piaB qPCR (alone and in combination) for detection of pneumococci in 250 OP samples
| Target gene(s) | No. of: | ||||||
|---|---|---|---|---|---|---|---|
| True positives | False positives | False negatives | True negatives | PPV (%) | Specificity (%) | Sensitivity (%) | |
|
| 10 | 29 | 1 | 210 | 26 | 88 | 91 |
|
| 10 | 68 | 1 | 171 | 13 | 72 | 91 |
|
| 10 | 20 | 1 | 219 | 33 | 92 | 91 |
| 10 | 14 | 1 | 225 | 42 | 94 | 91 | |
| 9 | 11 | 2 | 228 | 45 | 95 | 82 | |
| 9 | 10 | 2 | 229 | 47 | 96 | 82 | |
| 9 | 8 | 2 | 231 | 53 | 97 | 82 | |
A positive is defined as any C of <40.
Positive predictive value (PPV), specificity, and sensitivity were compared to DNA microarray, the study gold standard for pneumococcus-positive samples.
FIG 1(a) Frequency of pneumococcal serotypes detected in NP samples. (b and c) Pneumococcal capsular genes detected in OP samples from S. pneumoniae (serotypes) (b) or other species (pseudoserotypes) (c). *, others include 9V, 9L, 18A-like, 18C-like, 20-like, 33F-like, 37, 41F-like, 47A, NT3a, and NT4a (all n = 2) and 1, 41A, 7A-like, 7F, 9A, 9N-like, 10F, 13-like, 17A-like, 17-like, 20A, 22A, 24B-like, 28A-like, 32F-like, 33B-like, 35B, 35F-like, 40, 41A-like, 46, and 48 (all n = 1).
Detailed microbiological analysis of 11 OP samples using lytA qPCR, microarray, latex sweep agglutination, and multiplex PCR
| Sample ID | Microarray PathID | Microarray serotyping | Latex sweep agglutination | mPCR | mPCR serotyping | |
|---|---|---|---|---|---|---|
| FVEP-002-004 | Equivocal (39.52) | SP-3/5 | 9A-like* (34%) + 7F-like* (26%) + 36-like* (17%) + NT4b* (17%) + 27-like* (6%) | 4 + 9L + 36 + 15 | Positive | 7F/7A + 24F/24A/24B + 10F/10C/33C + 9N/9L |
| FVEP-002-418 | Equivocal (38.48) | SP-3/5 | NT4a* (53%) + 24A-like* (21%) + NT4b* (11%) + 43/39-like* (9%) + 16A-like* (3%) + 28A-like* (2%) + 4-like* (1%) | 24A | Negative | 33F/33A/37 + 35B + 24F/24A/24B + 4 + 10F/10C/33C + 35A/35C/42 + 9N/9L |
| FVEP-002-496 | Equivocal (37.93) | SP-3/5 | 10C/21-like* (41%) + NT4a* (20%) + 36-like* (12%) + 39-like* (8%) + 16A-like* (8%) + 48-like* (4%) + 24A-like* (4%) + 45-like* (2%) + 19B-like* (1%) | NSD | Positive | 22F/22A + 24F/24A/24B + 10A + 10F/10C/33C + 20 + 13 |
| FVEP-002-460 | Equivocal (35.82) | SP-5/5 | NT4b* (35%) + 10C/21-like* (29%) + 48-like* (11%) + 41A (7%) + 20-like* (5%) + 23F (4%) + 35A-like* (4%) + 5-like* (3%) + 16A-like* (2%) | NSD | Positive | 6A/6B/6C/6D + 6C/6D + 22F/22A + 33F/33A/37 + 35B + 4 + 23F + 10A + 10F/10C/33C + 5 + 35A/35C/42 + 34 + 21 + 20 |
| FVEP-002-002 | Equivocal (37.79) | SP-3/5 | NT4b* (46%) + 33A-like* (40%) + 9V (5%) + 18F-like (4%) + 35A-like (4%) + 19B-like (1%) | 12 + 33 + 35B | Positive | 6A/6B/6C/6D + 19A + 33F/33A/37 + 38/25F/25A + 35B + 10A + 10F/10C/33C + 35A/35C/42 |
| FVEP-002-084 | Equivocal (37.57) | SP-3/5 | NT4b* (62%) + 36-like* (25%) + 5-like* (7%) + 19B-like* (5%) + 9N-like* (1%) | 19B | Positive | 4 + 5 + 9N/9L |
| FVEP-002-488 | Equivocal (39.82) | SP-3/5 | NT4b* (45%) + 48-like* (36%) + 19B-like* (11%) + 43/39-like* (8%) | NSD | Negative | 38/25F/25A + 4 + 23F + 39 + 10F/10C/33C + 34 + 21 + 20 + 6A/6B/6C/6D |
| FVEP-002-078 | Positive (28.44) | SP-3/5 | NT4b* (26%) + 10C/21-like* (26%) + 7F-like* (26%) + 16A-like* (11%) + 45-like* (6%) + 9L-like* (5%) | 35B | Positive | 15A/15F + 7F/7A + 24F/24A/24 + 4 + 10F/10C/33C + 9N/9L + 21 + 20 |
| FVEP-002-080 | Positive (34.41) | SP-5/5 | NT4b* (32%) + 48-like* (27%) + 24B (20%) + 19B-like* (13%) + 1 (8%) | 19B | Positive | 24F/24A/24B + 1 + 9N/9L + 13 |
| FVEP-002-422 | Positive (34.70) | SP-3/5 | NT4b* (42%) + 10C/21-like* (42%) + 19C-like* (12%) + 16A-like* (4%) | NSD | Positive | 15B/15C + 10F/10C/33C + 21 + 17F |
| FVEP-002-486 | Equivocal (35.29) | SP-3/5 | NT4b* (71%) + 10C/21-like* (17%) + 11B-like* (5%) + 16A-like* (5%) + 19C-like* (2%) | NSD | Positive | 15A/15F + 10F/10C/33C + 35A/35C/42 + 9N/9L + 31 + 20 |
C, cycle threshold value for lytA qPCR (C of < 35, positive; C of 35 to 40, equivocal; no C, negative).
SP-5/5 result for the PathID component on microarray indicates a sample positive for S. pneumoniae; SP-4/5 or less indicates that S. pneumoniae is not present.
Pseudoserotypes are marked by “*” indicating that the result is likely from a nonpneumococcal bacterial species and “-like” indicating a partial or divergent set of capsule genes.
cpsA in mPCR is used as a positive control for pneumococci.
Each sample also had additional mPCR products that did not correlate with an expected mPCR serotype product size that are not listed here.
NSD, no serotype detected.
FIG 2MALDI-TOF MS identification (a), latex agglutination (b), and microarray serotyping (c) results for 88 nonpneumococcal isolates subcultured from 11 OP samples. These data do not include results from 33 isolates that were not able to be tested by latex agglutination or from 47 isolates that were not tested by microarray for practical reasons.
FIG 3Comparison of the capsule gene locus for isolate FVEP-002-080-02 (a) with serotype 19B (GenBank accession no. CR931676.1) and the capsule gene locus for isolate FVEP-002-002-03 (b) with serotype 33F (GenBank accession no. AJ006986.1). Sequence identity (percent) between the two sets of genes is shown. Genes are categorized according to characteristics used by Bentley et al. (53). Green boxes around genes indicate that a gene was categorized as present by microarray serotyping.
FIG 4Experimental procedures for OP samples and isolates. gHBA, gentamicin horse blood agar.